Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2014-10-31
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
E. Coli Nissle 1917 - Suspension for Infection Prophylaxis
NCT02802059
The Effect of Probiotics on E. Coli Gastroenteritis
NCT01225042
The Effect of Probiotics on E. Coli-induced Gastroenteritis
NCT01709266
Efficacy and Safety of E.Coli Nissle 1917 in Patients With Mild (Stage 1-2) or Minimal Hepatic Encephalopathy
NCT04787276
Safety and Viability of an E. Coli Nissle Colibactin Knockout in Healthy Volunteers
NCT05816577
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Purpose: The Phase 1 trial will use Nissle 1917 in healthy adult patient volunteers for the first time in the United States. The investigators will track the frequency and incidence of side effects and adverse events.
Participants:
20 adult (\>21 years of age) healthy volunteers
Protocol:
* Participants will enroll in our trial after a review of medical history and physical.
* Participants will then take 30 day course of Nissle 1917 capsules
* Investigators will telephone participants 1-2 weeks after they have begun the trial to assess for any side effects or adverse events
* Subjects will also be provided with a diary to record any side effects or adverse events
* At the end of 30 days, participants will return to clinic for a follow up visit to discuss any side effects or adverse events experienced during the trial and to return any unused medication
* Investigators will again telephone all participants 28-35 days following completion of the study drug again to pose a questionnaire aimed at revealing any side effects or adverse events.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction. The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days. Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
E. coli Nissle 1917
Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E. coli Nissle 1917
Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Any individual with an acute illness within the past 7 days
* Any individual with neurogenic bladder or with vesicoureteral reflux
* Any individual with any anatomic abnormality, congenital or acquired, of the urinary tract system
* Any individual with any anatomic abnormality, congenital or acquired, of the gastrointestinal tract
* Any individual with untreated dysfunctional elimination syndrome
* Immunocompromised patients
* Individuals with a central venous catheter
* Individuals requiring the use of antibiotics, immunomodulatory medications, or other probiotics
* Any participant with a history of chronic gastrointestinal disease
* Any individual with a chronic uncontrolled medical illness
* Any female of reproductive age who is currently pregnant, breastfeeding, or sexually active and unwilling or unable to use an acceptable method of contraception.
* Any participant is unable to appropriately take and store medication
* Any individual enrolled in a clinical trial evaluating another investigational agent in the last 30 days.
21 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Elizabeth Lucas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elizabeth Lucas
Principal Invesgator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Venkata R Jayanthi, MD
Role: PRINCIPAL_INVESTIGATOR
Nationwide Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nationwide Children's Hospital
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB14-00586
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.